TECHNOLOGY LICENSING OPPORTUNITY: Bacterial Lipid Nanodiscs Platform
- Client
- Department of Energy
- RFP Number
- —
- Posted
- —
- Category
- US Federal
- Budget
- —
- NAICS
- 541715
- Set-aside
- No Set aside used
- Contact
- Caleb Ledgerwood
- [email protected]
Description
AI GeneratedThe buyer seeks technology licensing for a Bacterial Lipid Nanodiscs Platform. This platform creates uniform nanoscale discs from total lipid extracts harvested from bacterial membranes, encasing the lipid mixture with a membrane scaffold protein to form a stable disc. The platform preserves the full complement of native bacterial lipids in a membranelike environment, enabling accurate evaluation of immunogenic lipids and membrane-associated targets without handling live high-risk pathogens. The technology supports vaccine design and antimicrobial discovery. The buyer has identified antibodies specific to E. coli LPS and Y. pestis membrane lipids using this platform, which are independently licensable.
Official SAM.gov notice
- Solicitation number
- S-191192
- Agency
- Department of Energy
- Buying office
- Triad - DOE Contractor
- Notice type
- Special Notice
- Responses due
- Dec 15, 2026, 7:00 PM ET
- Posted on SAM.gov
- Jun 15, 2026
- NAICS
- 541715 · Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Product/service code
- AJ11
- Set-aside
- No Set aside used
- Place of performance
- LOS Alamos, NM, 87545
- Contracting contact
- Caleb Ledgerwood
[email protected] - Additional contact
- Lindsay Augustyn
[email protected]
Read the official notice description
The Bacterial Lipid Nanodiscs Platform developed by Los Alamos National Laboratory provides a new way to study entire bacterial membranes in a controlled, nanoscale format derived directly from native lipid extracts. Researchers gain access to membrane components that typically remain difficult to isolate, stabilize or analyze, enabling more accurate evaluation of immunogenic lipids and membrane?associated targets. The platform offers a safer alternative to handling live high?risk pathogens while preserving the biological context that drives meaningful insights for vaccine design and antimicrobial discovery such as therapeutic antibodies to conserved lipids on bacterial membranes. How it Works The Bacterial Lipid Nanodiscs Platform creates uniform nanoscale discs from total lipid extracts harvested from bacterial membranes. Membrane scaffold protein MSP1D1 encases the lipid mixture and forms a stable disc roughly 10 nanometers wide. The resulting particles retain the full complement of native bacterial lipids, arranged in a membrane?like environment that supports realistic biological interactions without requiring synthetic lipids or live cells. Technical Description The method adapts established nanodisc assembly techniques to incorporate entire bacterial lipid extracts rather than defined synthetic lipid mixtures. Total lipids from a pathogen are solubilized, combined with MSP1D1 and dialyzed under controlled conditions to allow the scaffold protein to form a discoidal structure around the heterogeneous lipid population. The process yields nanoparticles that represent the membrane environment of the source organism, including amphiphilic molecules that typically resist purification or structural study when isolated from their native context. The approach was demonstrated using Yersinia pestis, chosen to illustrate how membrane characterization can proceed without the hazards associated with live Tier 1 pathogens. The method captures lipopolysaccharides (LPS) and diverse immunogenic lipids in an arrangement that mirrors their natural organization. Researchers can evaluate binding interactions, immune?stimulating properties and potential antigenic targets in a stable platform that avoids the limitations of outer membrane vesicle purification. Furthermore, using this platform we have identified antibodies specific to E. coli LPS and Y. pestis membrane lipids. These antibodies are independently licensable. Advantages • Provides membrane?like structures using native bacterial lipids • Avoids the safety challenges of handling live pathogens • Offers a broader and more realistic lipid environment than synthetic nanodiscs • Enables improved assessment of membrane antigens and immune responses • Supports analysis of diverse bacterial species using a unified workflow • Creates consistent nanoscale particles suitable for research and development settings Market Applications • Life Sciences Research (membrane biology, immunology) • Vaccine Development (bacterial antigen discovery) • Drug Discovery (membrane?associated targets) • Diagnostics (lipid biomarker exploration) • Biodefense Research (safe pathogen characterization) Development Status: TRL 3 U.S. Patent pending LA-UR-26-24920 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected]. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology m.lanl.gov/tech-search
Source: SAM.gov contract opportunities data (U.S. federal public data).
Incumbent
No incumbent history found for this requirement. The notice does not cite a current contract, and no earlier award from this buying office matches it.
Market context
Awards in the same category (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)). This is not this requirement's award history.
Recent similar awards: Department of Energy, NAICS 541715
| Vendor and award | Value | Ends |
|---|---|---|
| SURATECH LLC89243126CSC000213 · MANAGEMENT AND OPERATING CONTRACTOR FOR THE THOMAS JEFFERSON NATIONAL ACCELERATOR FACILITY | $304.7M | May 31, 2031 |
| BATTELLE SAVANNAH RIVER ALLIANCE, LLC89303321CEM000080 · SAVANNAH RIVER NATIONAL LABORATORY MANAGEMENT AND OPERATING (M&O) CONTRACT | $1.6B | Feb 15, 2030 |
| FERMI FORWARD DISCOVERY GROUP, LLC89243024CSC000002 · MANAGEMENT AND OPERATING CONTRACT FOR THE FERMI NATIONAL ACCELERATOR LABORATORY (FNAL) | $2.5B | Dec 31, 2029 |
| GENERAL ATOMICS89233124CNA000365 · RESEARCH & DEVELOPMENT AND FABRICATION OF INERTIAL CONFINEMENT FUSION (ICF) TARGETS FOR TH | $92.4M | Sep 30, 2029 |
| LEIDOS, INC.89243318CFE000003 · RESEARCH SUPPORT SERVICES (RSS) | $1.1B | Dec 30, 2028 |
Top vendors in this category: Department of Energy, NAICS 541715, since Oct 1, 2023
34 contract awards in this NAICS over the period.
- 1. FLUOR MARINE PROPULSION, LLC$5.5B
- 2. FERMI FORWARD DISCOVERY GROUP, LLC$2.5B
- 3. BATTELLE SAVANNAH RIVER ALLIANCE, LLC$990.2M
- 4. LEIDOS, INC.$478.6M
- 5. SURATECH LLC$304.7M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.
Source and verification
Original sourceCraxy AI summarizes this opportunity from the original listing and available solicitation documents. Confirm submission instructions and amendments with the issuing source before responding.
Personalized fit score
Sign up free to see how well this opportunity fits your company — based on your saved profile.
Sign up to see your fit score